{"nctId":"NCT00210353","briefTitle":"Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma","startDateStruct":{"date":"2003-01"},"conditions":["Lymphoma, Mucosa-Associated Lymphoid Tissue"],"count":454,"armGroups":[{"label":"ARM A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: chlorambucil (drug)"]},{"label":"ARM B","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab+chlorambucil"]},{"label":"ARM C (Since April 2006)","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab"]}],"interventions":[{"name":"chlorambucil (drug)","otherNames":[]},{"name":"rituximab+chlorambucil","otherNames":[]},{"name":"rituximab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site\n2. any stage (Ann Arbor I-IV)\n3. either de novo, or relapsed disease following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma)\n4. no evidence of histologic transformation to a high grade lymphoma\n5. measurable or evaluable disease\n6. age \\> 18\n7. life expectancy of at least 1 year\n8. ECOG performance status 0-2\n9. no prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer\n10. no prior chemotherapy\n11. no prior immunotherapy with any anti-CD20 monoclonal antibody\n12. no prior radiotherapy in the last 6 weeks\n13. no corticosteroids during the last 28 days, unless prednisone chronically administered at a dose \\<20 mg/day for indications other than lymphoma or lymphoma-related symptoms\n14. no evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry\n15. no evidence of symptomatic central nervous system (CNS) disease\n16. no impairment of bone marrow function (WBC \\>3.0x109/L, ANC \\>1.5x109/L, PLT \\>100x109/L), unless due to lymphoma involvement\n17. no major impairment of renal function (serum creatinine \\<1,5x upper normal) or liver function (ASAT/ALAT \\<2,5 upper normal, total bilirubin \\<2,5x upper normal), unless due to lymphoma involvement\n18. no evidence of active opportunistic infections\n19. no known HIV infection\n20. no active HBV and/or HCV infection\n21. no pregnant or lactating status\n22. appropriate contraceptive method in women of childbearing potential or men\n23. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n24. informed consent must be given according to national/local regulations before randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free-survival (EFS)","description":"Percentage of patients without events (failure of treatment or Death from any cause) after 5 years from trial registration","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete and Partial Remission Rate - Percentage of Patients With Complete and Partial Response at the End of Treatment","description":"Response criteria were defined according to the NCI standardized response criteria for non-Hodgkin's lymphoma.\n\nComplete response. Disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease-related symptoms, if present before therapy, and normalization of those biochemical abnormalities definitely assignable to NHL. Regression of all lymph nodes and nodal masses to normal (≤ 1.5 cm in their greatest transverse diameter for nodes \\> 1.5 cm before therapy and to ≤ 1 cm for nodes that were 1.1-1.5 cm. Regression by more than 75% in the sum of the products of the greatest diameters).\n\nPartial response. Decrease by at least 50% in SPD of the six largest measurable lesions. It is not necessary for all lesions to have regressed to qualify for partial response, but no lesion should have progressed and no new lesion should appear.\n\nFor primary gastric sites, response was based on GELA histologic grading system.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"94.7","spread":null},{"groupId":"OG002","value":"78.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Duration (Time to Relapse or Progression) - Percentage of Patients in Continuous Remission at Five Years From Trial Registration","description":"Response criteria were defined according to the NCI standardized response criteria for non-Hodgkin's lymphoma.\n\nComplete response (CR). Disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease-related symptoms, if present before therapy, and normalization of those biochemical abnormalities definitely assignable to NHL. Regression of all lymph nodes and nodal masses to normal (≤ 1.5 cm in their greatest transverse diameter for nodes \\> 1.5 cm before therapy and to ≤ 1 cm for nodes that were 1.1-1.5 cm. Regression by more than 75% in the sum of the products of the greatest diameters).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free-survival (PFS)","description":"Percentage of patients without disease progression after 5 years from trial registration","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Percentage of patients alive after 5 years from trial registration","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":131},"commonTop":["Fatigue","Infection","Infusion related reactions","Nausea","Abdominal pain upper"]}}}